Tags

Type your tag names separated by a space and hit enter

Why Is Rapamycin Not a Rapalog?
Gerontology. 2023; 69(6):657-659.G

Abstract

Rapamycin (sirolimus) is an immunosuppressive drug approved by the Food and Drug Administration (FDA). It is also a leading candidate for targeting aging. Rapamycin and its analogs (everolimus, temsirolimus, ridaforolimus) inhibit the mammalian target of rapamycin (mTOR) kinase by binding to FK506-binding proteins (FKBP) and have a similar chemical structure that only differs in the functional group present at carbon-40. Analogs of rapamycin were developed to improve its pharmacological properties, such as low oral bioavailability and a long half-life. The analogs of rapamycin are referred to as "rapalogs." Rapamycin is the parent compound and should therewith not be called a "rapalog."

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Kuerec AH
Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, dr.ajlahodzic@gmail.com. Centre for Healthy Longevity, @AgeSingapore, National University Health System, Singapore, Singapore, dr.ajlahodzic@gmail.com.
Maier AB
Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Centre for Healthy Longevity, @AgeSingapore, National University Health System, Singapore, Singapore. Vrije Universiteit Amsterdam, Department of Human Movement Sciences, @AgeAmsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands.

MeSH

HumansMTOR InhibitorsSirolimusImmunosuppressive AgentsEverolimus

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

36617414

Citation

Kuerec, Ajla Hodzic, and Andrea B. Maier. "Why Is Rapamycin Not a Rapalog?" Gerontology, vol. 69, no. 6, 2023, pp. 657-659.
Kuerec AH, Maier AB. Why Is Rapamycin Not a Rapalog? Gerontology. 2023;69(6):657-659.
Kuerec, A. H., & Maier, A. B. (2023). Why Is Rapamycin Not a Rapalog? Gerontology, 69(6), 657-659. https://doi.org/10.1159/000528985
Kuerec AH, Maier AB. Why Is Rapamycin Not a Rapalog. Gerontology. 2023;69(6):657-659. PubMed PMID: 36617414.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Why Is Rapamycin Not a Rapalog? AU - Kuerec,Ajla Hodzic, AU - Maier,Andrea B, Y1 - 2023/01/07/ PY - 2022/09/07/received PY - 2022/12/22/accepted PY - 2023/6/7/medline PY - 2023/1/9/pubmed PY - 2023/1/8/entrez KW - Aging KW - Mammalian target of rapamycin inhibitors KW - Sirolimus SP - 657 EP - 659 JF - Gerontology JO - Gerontology VL - 69 IS - 6 N2 - Rapamycin (sirolimus) is an immunosuppressive drug approved by the Food and Drug Administration (FDA). It is also a leading candidate for targeting aging. Rapamycin and its analogs (everolimus, temsirolimus, ridaforolimus) inhibit the mammalian target of rapamycin (mTOR) kinase by binding to FK506-binding proteins (FKBP) and have a similar chemical structure that only differs in the functional group present at carbon-40. Analogs of rapamycin were developed to improve its pharmacological properties, such as low oral bioavailability and a long half-life. The analogs of rapamycin are referred to as "rapalogs." Rapamycin is the parent compound and should therewith not be called a "rapalog." SN - 1423-0003 UR - https://www.unboundmedicine.com/medline/citation/36617414/Why_is_rapamycin_not_a_rapalog DB - PRIME DP - Unbound Medicine ER -